Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva; Daniel A. Pollyea; Jalaja Potluri; Brenda Chyla; Leah J. Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L. Ricker; William Blum; Courtney D. DiNardo; Tapan M. Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Johansson; Rod Humerickhouse; Mack Mabry; Richard M. Stone; Hagop M. Kantarjian; Anthony Letai

doi:10.1158/2159-8290.cd-16-0313

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Venetoclax monotherapy demonstrated clinical activity in patients with AML (relapsed/refractory or unfit for intensive chemotherapy) with a tolerable safety profile in this phase II study. Predictive markers of response consistent with BCL2 dependence were identified. Clinical and preclinical findings provide a compelling rationale to evaluate venetoclax combined with other agents in AML. Cancer Discov; 6(10); 1106-17.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Konopleva et al. (2016) studied this question.

synapsesocial.com/papers/69d76b7ef44a16d01ef30e2c https://doi.org/10.1158/2159-8290.cd-16-0313

View Full Paper

Ask AI

Bookmark

Share

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading